Tuesday, January 29, 2013

Glaxo Starts India Venture to Develop Emerging Market Vaccines


GlaxoSmithKline Plc (GSK) agreed to form a joint venture in India to produce a six-in-one vaccine that will immunize children in developing countries against infectious diseases including polio.

The London-based drugmaker has agreed to form a 50-50 venture with India’s Biological E Ltd. to develop a product that would combine Glaxo’s injectable polio shot with a vaccine produced by Biological E that protects against five diseases including diphtheria and tetanus, the companies said in an e- mailed statement on Jan. 28.

For the complete article, click here...
  • Managing Partners

    William Davidson Institute
  • Sponsoring Partner

    Citi Foundation
  • Content Partners


Have an Idea for a Story?Have an Idea for a Story?

Make A Suggestion

Social MediaSocial Media

Facebook Twitter

Story Snapshot